Skip to main content
OpenTrials
Completed

NCT Number: NCT06899620

BC179 Relieves Discomfort After Drinking

To assess the effectiveness and safety of probiotic strain BC179 in reducing alcohol absorption in the gut, thereby lowering health risks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Drinking Behavior Behavior

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wu Ying

Luoyang, Henan, 471000, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

  • Inclusion Criteria:
  • Participants must be aged between 18 and 65 years.
  • They should have a documented history of long-term alcohol consumption, defined as consuming at least 20 grams of ethanol per day for at least one year. This is calculated using the formula: volume (mL) × alcohol content (%) × 0.8.
  • They must provide written informed consent and be willing to comply with the study procedures.
  • Exclusion Criteria:
  • History of chronic liver, gastrointestinal, or systemic metabolic disorders.
  • Use of products with similar functions to the investigational formulation within the past two weeks.
  • Use of antibiotics, laxatives, or dietary supplements within the past four weeks.
  • Documented history of hypertension or diabetes.
  • Severe allergies or immune deficiencies.
  • Pregnancy, lactation, or planning pregnancy without effective contraception during the study period.

Treatment and study plan

Probiotic group

Dietary Supplement

The experimental phase of this study lasted for 60 days.

Placebo Group

Dietary Supplement

The experimental phase of this study lasted for 60 days.

Primary outcomes

  1. Effects of BC179 on alcohol metabolism

    Time frame: 60 days

    The impact of BC179 on alcohol metabolism is assessed by monitoring blood alcohol concentration (BAC) and related enzyme activities, such as alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).

Sponsors and collaborators

Lead sponsor

Wecare Probiotics Co., Ltd.

Industry

Registry information

Official study title

Weizmannia Coagulans BC179 Alleviates Post-Alcohol Discomfort May Via Taurine-Related Metabolism and Antioxidant Regulation: A Randomized, Double-Blind，Placebo-Controlled Trial

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Mar 28, 2025
Registry last updated
Aug 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.